Fifty-four outpatients with endoscopicaily diagnosed benign gastric ulcer were allocated at random to treatment with either cimetidine 800 mg daily for six weeks or carbenoxolone sodium 300 mg daily for one week then 150 mg daily for five weeks. Ulcers were reassessed by endoscopy at the end of the trial. The endoscopist was unaware of the treatment and did not take part in the clinical care of the patients.
Summary and conclusions
Fifty-four outpatients with endoscopicaily diagnosed benign gastric ulcer were allocated at random to treatment with either cimetidine 800 mg daily for six weeks or carbenoxolone sodium 300 mg daily for one week then 150 mg daily for five weeks. Ulcers were reassessed by endoscopy at the end of the trial. The endoscopist was unaware of the treatment and did not take part in the clinical care of the patients.
Twenty-one of the 27 patients (78%) given cimetidine and 14 of the 27 (52%) given carbenoxolone had healed ulcers. Symptomatic response occurred earlier with cimetidine but was not significantly better. Unwanted effects were more common in the carbenoxolone group: 12 patients developed hypokalaemia, four of whom needed oral potassium supplements.
The results suggest that histamine H ,-receptor blockade is at least as effective as carbenoxolone sodium for benign gastric ulcer and produces fewer side effects.
Department of Gastroenterology, Central Middlesex Hospital,
Introduction
Controlled trials have suggested that carbenoxolone sodium accelerates the healing of gastric ulcer, but side effects limit the freedom with which it may be used, especially in the elderly. ' 2 Despite this it has been generally accepted in the treatment of benign gastric ulcer. Early, uncontrolled studies showed that the H,-receptor antagonist cimetidine might be effective in benign gastric ulcer and free of unwanted side effects.3 In a later, controlled trial cimetidine was found to be significantly better than a placebo. 4 We report the results of a controlled study comparing cimetidine 800 mg/day for six weeks with the recommended dose of carbenoxolone sodium in the short-term treatment of benign gastric ulcer.
Patients and methods
On study day 0 a lesser-curve gastric ulcer was diagnosed endoscopically. Four quadrant biopsy specimens and brush-cytological smears were taken from each ulcer, and blood was obtained for routine haematological and biochemical safety screening. All Patients were seen again on day 7. Those fulfilling the criteria for the trial were allocated at random to treatment with either cimetidine 200 mg four times daily after meals for six weeks or carbenoxolone sodium 100 mg thrice daily for one week then 50 mg thrice daily for five weeks. All patients were seen weekly. At each visit diary cards and unused antacid and trial tablets were collected and a new supply issued. The frequency of pain and antacid consumption were recorded, the patient weighed and examined, and blood obtained for routine haematological and biochemical studies.
Within three days after the end of the six-week course of treatment each patient underwent repeat endoscopy, the result being recorded as "ulcer healed" or "ulcer not healed." The same endoscopist performed both examinations. The endoscopist had no part in clinical management and remained unaware of the patients' treatment.
Results were analysed using Fisher's exact test of significance for ulcer healing and the Mann-Whitney U test to compare the incidence of pain and antacid consumption in the treatment groups.
Results
Fifty-seven patients (25 women, 32 men) entered the trial. Three were excluded from the analysis: one in each treatment group defaulted, and in the third (given carbenoxolone) gastric cancer was diagnosed histopathologically at the second endoscopy. Four patients did not complete the 42 days of treatment but are included in the analysis. One of these, in the carbenoxolone group, was withdrawn after 24 days because of hypertension. At endoscopy the ulcer was seen to have healed. The other three patients, two given cimetidine and one carbenoxolone, were endoscoped after 35 days because of their holiday arrangements.
Of the 54 patients included in the analysis, 27 received cimetidine and 27 carbenoxolone sodium (see Ulcer healing-Ulcers healed in 21 (78%) patients in the cimetidine group and 14 (52%) in the carbenoxolone group. This difference was not significant (P = 0-086).
Unwanted effects-Subjective unwanted effects were reported by 10 patients taking cimetidine and 17 taking carbenoxolone sodium. These included dizziness, nausea, vomiting, insomnia, and drowsiness. Two patients taking cimetidine developed a mild acneiform rash but continued with treatment. The rash disappeared when treatment was 
Discussion
The proportion of gastric ulcers healing with cimetidine in this study agrees with findings in studies comparing cimetidine with placebo.4-6 In a multicentre trial5 7O08, of patients given cimetidine had healed gastric ulcers, which constituted a significant advantage (P <0 02) over placebo. Machell et a16 reported that 69% of gastric ulcers had healed at the end of four weeks' treatment with cimetidine and 54% healed after placebo. The results of Frost et a14 were similar, with 78% of gastric ulcers healing with cimetidine compared with only 27% healing with placebo (P <0 002). In another trial comparison of cimetidine with carbenoxolone just reached conventional levels of significance in favour of cimetidine, but few patients were treated. In that study 41% of ulcers healed after four weeks of cimetidine 1 g daily, but all healed after three months of treatment.
I
In our trial 78% of gastric ulcers healed with cimetidine and 52% healed with carbenoxolone sodium. Although this difference is not significant, the unwanted effects of cimetidine were minimal as compared with those of carbenoxolone sodium, 44% of patients given carbenoxolone developing peripheral oedema or hypokalaemia.
Our results therefore show that cimetidine is at least as effective as carbenoxolone sodium for gastric ulcer and causes fewer unwanted effects.
